155 lines
59 KiB
Text
155 lines
59 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-toc">
|
|
<meta name="ncbi_acc" content="NBK589218">
|
|
<meta name="ncbi_domain" content="niceng226er12">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK589218/?report=reader">
|
|
<meta name="ncbi_pagename" content="Evidence review for regular follow-up and review - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="toc">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Evidence review for regular follow-up and review - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="1">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE,NOIMAGEINDEX">
|
|
<meta name="citation_title" content="Evidence review for regular follow-up and review">
|
|
<meta name="citation_publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="citation_date" content="2022/10">
|
|
<meta name="citation_pmid" content="36791243">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK589218/">
|
|
<meta name="citation_keywords" content="Osteoarthritis">
|
|
<meta name="citation_keywords" content="Aftercare">
|
|
<meta name="citation_keywords" content="Quality of Life">
|
|
<meta name="citation_keywords" content="Adolescent">
|
|
<meta name="citation_keywords" content="Young Adult">
|
|
<meta name="citation_keywords" content="Adult">
|
|
<meta name="citation_keywords" content="Middle Aged">
|
|
<meta name="citation_keywords" content="Aged">
|
|
<meta name="citation_keywords" content="Aged, 80 and over">
|
|
<meta name="citation_keywords" content="Humans">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Evidence review for regular follow-up and review">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="DC.Date" content="2022/10">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK589218/">
|
|
<meta name="og:title" content="Evidence review for regular follow-up and review">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK589218/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng226er12-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/niceng226er12/toc/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK589218/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8DF57A7D6CD6710000000000A20089.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK589218/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-cmap-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK589218/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK589218/&text=Evidence%20review%20for%20regular%20follow-up%20and%20review"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-cmap-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">In Page Navigation</div></div><div class="cnt lol f1"><a href="/books/n/niceercollect/?report=reader">NICE Evidence Reviews Collection</a><a class="current">Title Information</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK589218/?report=classic">Switch to classic view</a><a href="/books/n/niceng226er12/pdf/">PDF (563K)</a><a href="/books/n/niceng226er12/toc/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK589218%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8DF57A7D6CD6710000000000A20089.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style"><div class="fm-sec bkr_bottom_sep"><div class="bkr_thumb"><a href="https://www.nice.org.uk" title="National Institute for Health and Care Excellence (NICE)" class="img_link icnblk_img" ref="pagearea=logo&targetsite=external&targetcat=link&targettype=publisher"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng226er12-lrg.png" alt="Cover of Evidence review for regular follow-up and review" /></a></div><div class="bkr_bib"><h1 id="_NBK589218_"><span itemprop="name">Evidence review for regular follow-up and review</span></h1><div class="subtitle">Osteoarthritis in over 16s: diagnosis and management</div><p><b>Evidence review L</b></p><p><i>NICE Guideline, No. 226</i></p><div class="half_rhythm">London: <a href="https://www.nice.org.uk" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=publisher"><span itemprop="publisher">National Institute for Health and Care Excellence (NICE)</span></a>; <span itemprop="datePublished">2022 Oct</span>.<div class="small">ISBN-13: <span itemprop="isbn">978-1-4731-4740-9</span></div></div><div><a href="/books/about/copyright/">Copyright</a> © NICE 2022.</div></div><div class="bkr_clear"></div></div><div id="niceng226er12.s1"><h2 id="_niceng226er12_s1_">1. Follow-up and review</h2><div id="niceng226er12.s1.1"><h3>1.1. Review question</h3><p>Is regular follow-up and review needed for people with osteoarthritis?</p><div id="niceng226er12.s1.1.1"><h4>1.1.1. Introduction</h4><p>Primary care is the most common first point of contact for people with osteoarthritis. Although some people may re-present to primary care over many years, some only present once and others never present. Patients with osteoarthritis may be prescribed potentially harmful medication or may have declining function, in which cases, timely review, intervention and reconsideration of the management plan would be beneficial. Adherence to management approaches such as exercise may be improved through follow-up. These issues have led to calls for regular, standardised reviews. However, the symptoms and function of people with osteoarthritis may vary from joint-to-joint and from person-to-person over time, this can necessitate frequent reviews over a short period of time. In such cases, a routine follow-up when the patient’s symptoms have settled may represent an unnecessary use of resource. It is important to have an effective system for achieving the best outcomes for people with osteoarthritis through balancing a proactive and a reactive approach to follow-up.</p><p>Current practice for people with osteoarthritis is to have symptom-led reviews and proactive medication reviews. Follow up is limited within NHS physiotherapy services and there can be long waiting times for specialist chronic pain services. There is not a standardised approach for follow up of a patient with osteoarthritis over time.</p><p>This review aims to determine if regular follow-up and review is beneficial for people with osteoarthritis. This question aims to answer:
|
|
<dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>A)</dt><dd><p class="no_top_margin">Is regular or symptom-led follow-up most beneficial?</p></dd></dl><dl class="bkr_refwrap"><dt>B)</dt><dd><p class="no_top_margin">If regular follow-up is beneficial, what is the frequency of follow up that is required (for example: more than once a year compared to once a year)?</p></dd></dl></dl></p></div><div id="niceng226er12.s1.1.2"><h4>1.1.2. Summary of the protocol</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng226er12tab1"><a href="/books/NBK589218/table/niceng226er12.tab1/?report=objectonly" target="object" title="Table 1" class="img_link icnblk_img figpopup" rid-figpopup="figniceng226er12tab1" rid-ob="figobniceng226er12tab1"><img class="small-thumb" src="/books/NBK589218/table/niceng226er12.tab1/?report=thumb" src-large="/books/NBK589218/table/niceng226er12.tab1/?report=previmg" alt="Table 1. PICO characteristics of review question." /></a><div class="icnblk_cntnt"><h4 id="niceng226er12.tab1"><a href="/books/NBK589218/table/niceng226er12.tab1/?report=objectonly" target="object" rid-ob="figobniceng226er12tab1">Table 1</a></h4><p class="float-caption no_bottom_margin">PICO characteristics of review question. </p></div></div><p>For full details see the review protocol in <a href="#niceng226er12.appa">Appendix A</a>.</p></div><div id="niceng226er12.s1.1.3"><h4>1.1.3. Methods and process</h4><p>This evidence review was developed using the methods and process described in <a href="https://www.nice.org.uk/process/pmg20/chapter/introduction-and-overview" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>. Methods specific to this review question are described in the review protocol in <a href="#niceng226er12.appa">Appendix A</a> and the methods document.</p><p>Declarations of interest were recorded according to <a href="https://www.nice.org.uk/about/who-we-are/policies-and-procedures" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NICE’s conflicts of interest policy</a>.</p></div><div id="niceng226er12.s1.1.4"><h4>1.1.4. Effectiveness evidence</h4><div id="niceng226er12.s1.1.4.1"><h5>1.1.4.1. Included studies</h5><p>No relevant clinical studies comparing different follow up and review strategies were identified.</p><p>See also the study selection flow chart in <a href="#niceng226er12.appc">Appendix C</a>.</p></div><div id="niceng226er12.s1.1.4.2"><h5>1.1.4.2. Excluded studies</h5><p>See the excluded studies list in <a href="#niceng226er12.appj">Appendix J</a>.</p></div></div><div id="niceng226er12.s1.1.5"><h4>1.1.5. Summary of studies included in the effectiveness evidence</h4><p>No evidence was identified for this review.</p></div><div id="niceng226er12.s1.1.6"><h4>1.1.6. Summary of the effectiveness evidence</h4><p>No evidence was identified for this review.</p></div><div id="niceng226er12.s1.1.7"><h4>1.1.7. Economic evidence</h4><div id="niceng226er12.s1.1.7.1"><h5>1.1.7.1. Included studies</h5><p>No health economic studies were included.</p></div><div id="niceng226er12.s1.1.7.2"><h5>1.1.7.2. Excluded studies</h5><p>No relevant health economic studies were excluded due to assessment of limited applicability or methodological limitations.</p><p>See also the health economic study selection flow chart in <a href="#niceng226er12.appg">Appendix G</a>.</p></div></div><div id="niceng226er12.s1.1.8"><h4>1.1.8. Summary of included economic evidence</h4><p>There was no economic evidence found.</p></div><div id="niceng226er12.s1.1.9"><h4>1.1.9. Economic model</h4><p>This area was not prioritised for new cost-effectiveness analysis.</p></div><div id="niceng226er12.s1.1.10"><h4>1.1.10. Unit costs</h4><p>Relevant unit costs are provided below to aid consideration of cost effectiveness.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng226er12tab2"><a href="/books/NBK589218/table/niceng226er12.tab2/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng226er12tab2" rid-ob="figobniceng226er12tab2"><img class="small-thumb" src="/books/NBK589218/table/niceng226er12.tab2/?report=thumb" src-large="/books/NBK589218/table/niceng226er12.tab2/?report=previmg" alt="Image " /></a><div class="icnblk_cntnt"><h4 id="niceng226er12.tab2"><a href="/books/NBK589218/table/niceng226er12.tab2/?report=objectonly" target="object" rid-ob="figobniceng226er12tab2">Table</a></h4></div></div></div><div id="niceng226er12.s1.1.11"><h4>1.1.11. Economic evidence statements</h4><div id="niceng226er12.s1.1.11.1"><h5>Economic</h5><ul><li class="half_rhythm"><div>No relevant economic evaluations were identified.</div></li></ul></div></div><div id="niceng226er12.s1.1.12"><h4>1.1.12. The committee's discussion and interpretation of the evidence</h4><div id="niceng226er12.s1.1.12.1"><h5>1.1.12.1. The outcomes that matter most</h5><p>The critical outcomes were quality of life, pain and physical function. These were considered critical due to their importance to people with osteoarthritis. The Osteoarthritis Research Society International (OARSI) consider that pain and physical function were the most important outcomes for evaluating interventions. Quality of life gives a broader perspective on the person’s wellbeing, allowing for examination of the biopsychosocial impact of interventions. Psychological distress, osteoarthritis flares, falls, residential service or hospital admission (including disability allowance use) and progression to joint replacement were the important outcomes.</p><p>The committee considered osteoarthritis flares to be important in the lived experience and management of osteoarthritis. However, these were also considered difficult to measure with no clear consensus on their definition. The Flares in OA OMERACT working group have proposed an initial definition and domains of OA flares through a consensus exercise; “it is a transient state, different from the usual state of the condition, with a duration of a few days, characterized by onset, worsening of pain, swelling, stiffness, impact on sleep, activity, functioning, and psychological aspects that can resolve spontaneously or lead to a need to adjust therapy.“. However, this has been considered to have limitations and has not been widely adopted. Therefore, the committee included the outcome accepting any reasonable definition provided by any studies discussing the event.</p><p>Mortality was considered as a composite of serious adverse events rather than as a discreet outcome and categorised as an important outcome. Osteoarthritis as a disease process is not considered to cause mortality by itself and mortality is an uncommon outcome from osteoarthritis interventions.</p><p>No evidence was identified for any of these outcomes in this review.</p></div><div id="niceng226er12.s1.1.12.2"><h5>1.1.12.2. The quality of the evidence</h5><p>No evidence was identified for this review.</p></div><div id="niceng226er12.s1.1.12.3"><h5>1.1.12.3. Committee consideration of advantages and disadvantages</h5><p>The committee considered the current use of follow up in the NHS referring to their expert opinion. In current practice, follow up would be symptom led follow up or osteoarthritis will be raised as a concern in consultations for other conditions where regular follow up is normal practice. On discussion, the committee agreed that symptom led follow up is likely to be appropriate in most scenarios, as people with osteoarthritis may be able to self-manage their condition effectively after initial information and guidance is provided to initiate management strategies. They considered the potential opportunity cost that could be generated from regular follow up, which considering the absence of evidence saying that there is benefit from this, reinforced this idea. Based on these factors the committee made recommendation 1.5.1.</p><p>However, the committee acknowledged that follow up should be focussed on the person’s needs and so symptom led follow up may not always be the only scenario where follow up is required. The committee noted some scenarios where additional follow up may be required:
|
|
<ul><li class="half_rhythm"><div>If any new medication or other intervention is started – The committee acknowledged that introducing new medication presented potential risks and benefits for the person, and that it was appropriate to review the medication with the person to ensure that it is appropriate for ongoing use. This includes ensuring that medication is only used for the minimal time period as advised in recommendation 1.4.1. Therefore, the committee recommended that additional follow up should be considered in this case. This follow up could be provided by anyone suitably qualified to provide it (for example: pharmacists, general practitioners). Furthermore, the committee acknowledged the need for follow up for any other intervention, including exercise. The committee agreed that providing effective information to manage expectations of the effects of treatment are important (such as acknowledging that people will initially experience discomfort from exercise, but if they persist then symptoms will likely improve). Reinforcing this idea may require additional follow up, allowing opportunities to emphasise positive behaviours and empathise with the challenges associated with the intervention.</div></li><li class="half_rhythm"><div>The circumstances affecting the ability of the patient to seek help for themselves – The committee noted that health inequalities exist where people may not be able to engage with their health and so seek help on this basis (for example: people with learning disabilities, or people with communication difficulties). Therefore, this model of follow up should be adjusted to the person’s needs to ensure that everyone can engage with their care and access the support they require.</div></li><li class="half_rhythm"><div>The severity of the patient’s symptoms or functional limitations – People who experience more significant symptoms that are affecting their daily life may require additional consultation to work on management plans which may include complex combinations of therapies and considerations for invasive procedures, such as surgery. The committee wished to ensure this group did not experience an unmet need due to gradual but progressive functional deterioration.</div></li></ul></p><p>All decisions about follow up should be made according to good practice as a shared decision, incorporating the values of the person with osteoarthritis and any healthcare professionals involved in their care. Additional information and recommendations to support those made in this guidance is available in the <a href="https://www.nice.org.uk/guidance/ng197" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NICE guidelines on Shared decision making</a> (NG197) and <a href="https://www.nice.org.uk/guidance/cg138/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NICE guidelines on Patient experience in adult NHS services</a> (CG138). Support should be provided in a manner tailored to the individual with their concerns taken into account. With all of this taken into account the committee agreed recommendation 1.5.2.</p><p>Furthermore, the committee acknowledged that setting clear times to follow up management strategies, if deemed important in a shared decision, is important. Clearly explaining expectations of what a positive treatment experience is like, and the potential problems that can be experienced, and setting a specific time for people to seek additional help in if the management is not improving their symptoms was agreed to be important. Therefore, the committee made recommendation 1.5.3.</p><p>When appointments are made to discuss osteoarthritis, this should be the focus of the appointment. People with osteoarthritis may have other conditions that require consideration. However, people may be experiencing significant problems with their osteoarthritis that could be managed effectively if discussed. Therefore, care should be provided in a holistic manner</p><p>The committee discussed the implications of osteoarthritis for patients who have multiple long term conditions and agreed that such individuals were at particular risk of long term deterioration due to polypharmacy, falls and interactions between the long term conditions. They recommended that people should refer to the <a href="https://www.nice.org.uk/guidance/ng56" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NICE guidelines on Multimorbidity: clinical assessment and management</a> (NG56) for additional guidance. Based on this the committee agreed recommendation 1.5.2.</p></div><div id="niceng226er12.s1.1.12.4"><h5>1.1.12.4. Cost effectiveness and resource use</h5><p>There were no published economic evaluations found. In the absence of clinical evidence, cost-effectiveness modelling was not feasible since a model would require good evidence of clinical effectiveness.</p><p>The committee used expert opinion to inform the recommendation that symptom-led follow-up is likely to be the most appropriate course of action in most cases, which is a departure from the previous recommendation where regular reviews were offered to all people with symptomatic osteoarthritis and annual reviews considered in people who had persistent/multiple joint problems, comorbidities or were taking regular medication for osteoarthritis. They also acknowledged that follow-up should be focussed on the person’s needs so there are some circumstances where additional follow-up may be required, for example if symptoms are very severe or if the person does not have the ability to seek help for themselves. This is a change from the previous guidelines where regular reviews of symptomatic osteoarthritis and annual reviews in people with joint symptoms/pain, comorbidities or multiple medications were recommended.</p><p>The committee’s decision to recommend symptom-led follow-up in place of regular reviews is a more efficient use of healthcare resources and may lead to cost-savings. This course of action also ensures that patients continue to receive the current standard of care.</p></div><div id="niceng226er12.s1.1.12.5"><h5>1.1.12.5. Other factors the committee took into account</h5><p>The committee noted that the osteoarthritis research in general does not appear to represent the diverse population of people with osteoarthritis. They agreed that any further research should be representative of the population, including people from different family backgrounds, and socioeconomic backgrounds, disabled people, and people of different ages and genders. Future work should be done to consider the different experiences of people from diverse communities to ensure that the approach taken can be made equitable for everyone. With this in mind the committee subgrouped their research recommendation by these protected characteristics where appropriate while suggesting that people from each group should be included in the research to ensure that it is applicable to the entire population.</p><p>The committee were aware that there is increasing use of telehealth appointments particularly with covid 19. Evidence comparing in person and telephone appointments was not included in the protocol for this review and therefore no recommendations have been made concerning this.</p></div></div><div id="niceng226er12.s1.1.13"><h4>1.1.13. Recommendations supported by this evidence review</h4><p>This evidence review supports recommendations 1.5.1 to 1.5.3 and the research recommendation on follow up. Other evidence supporting these recommendations can be found in evidence review L.</p></div><div id="niceng226er12.rl.r1"><h4>1.1.14. References</h4><dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd><div class="bk_ref" id="niceng226er12.ref1">Ahn
|
|
YH. Effects and costs of a community-based self-management support program for Korean medical aid beneficiaries with osteoarthritis: 12-month follow-up. Annals of the Rheumatic Diseases. 2016; 75(Suppl 2):1293</div></dd></dl><dl class="bkr_refwrap"><dt>2.</dt><dd><div class="bk_ref" id="niceng226er12.ref2">Curtis
|
|
L, Burns
|
|
A. Unit costs of health and social care 2020. Canterbury. University of Kent, 2020. Available from: <a href="https://www.pssru.ac.uk/project-pages/unit-costs/unit-costs-2020/" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">https://www<wbr style="display:inline-block"></wbr>​.pssru.ac<wbr style="display:inline-block"></wbr>​.uk/project-pages/unit-costs<wbr style="display:inline-block"></wbr>​/unit-costs-2020/</a></div></dd></dl><dl class="bkr_refwrap"><dt>3.</dt><dd><div class="bk_ref" id="niceng226er12.ref3">Hinman
|
|
RS, Campbell
|
|
PK, Lawford
|
|
BJ, Briggs
|
|
AM, Gale
|
|
J, Bills
|
|
C
|
|
et al
|
|
Does telephone-delivered exercise advice and support by physiotherapists improve pain and/or function in people with knee osteoarthritis?
|
|
Telecare randomised controlled trial. British Journal of Sports Medicine. 2020; 54(13):790–797 [<a href="https://pubmed.ncbi.nlm.nih.gov/31748198" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31748198</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>4.</dt><dd><div class="bk_ref" id="niceng226er12.ref4">National Institute for Health and Care Excellence. Developing NICE guidelines: the manual [updated October 2020]. London. National Institute for Health and Care Excellence, 2014. Available from: <a href="http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">http://www<wbr style="display:inline-block"></wbr>​.nice.org.uk<wbr style="display:inline-block"></wbr>​/article/PMG20/chapter<wbr style="display:inline-block"></wbr>​/1%20Introduction%20and%20overview</a></div></dd></dl><dl class="bkr_refwrap"><dt>5.</dt><dd><div class="bk_ref" id="niceng226er12.ref5">Ravaud
|
|
P, Flipo
|
|
RM, Boutron
|
|
I, Roy
|
|
C, Mahmoudi
|
|
A, Giraudeau
|
|
B
|
|
et al
|
|
ARTIST (osteoarthritis intervention standardized) study of standardised consultation versus usual care for patients with osteoarthritis of the knee in primary care in France: pragmatic randomised controlled trial. BMJ. 2009; 338:b421 [<a href="/pmc/articles/PMC2651104/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2651104</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19237406" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19237406</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>6.</dt><dd><div class="bk_ref" id="niceng226er12.ref6">Smith
|
|
T, Pickup
|
|
L, Evans
|
|
L, Latham
|
|
S, Conaghan
|
|
P. How often should i see the physiotherapist? a systematic review and meta-analysis investigating the relationship between number of physiotherapy contacts and efficacy when treating osteoarthritis of the knee. Rheumatology (United Kingdom). 2015; 54 (Suppl 1):i127</div></dd></dl><dl class="bkr_refwrap"><dt>7.</dt><dd><div class="bk_ref" id="niceng226er12.ref7">Wang
|
|
Q, Runhaar
|
|
J, Kloppenburg
|
|
M, Boers
|
|
M, Bijlsma
|
|
JW J, Bierma-Zeinstra
|
|
SM A
|
|
et al
|
|
Diagnosis of early stage knee osteoarthritis based on early clinical course: data from the CHECK cohort. Arthritis Research & Therapy. 2021; 23(1):217 [<a href="/pmc/articles/PMC8375192/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8375192</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34412670" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34412670</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>8.</dt><dd><div class="bk_ref" id="niceng226er12.ref8">Wetzels
|
|
R, van Weel
|
|
C, Grol
|
|
R, Wensing
|
|
M. Family practice nurses supporting self-management in older patients with mild osteoarthritis: a randomized trial. BMC Family Practice. 2008; 9:7 [<a href="/pmc/articles/PMC2235871/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2235871</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18226255" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18226255</span></a>]</div></dd></dl></dl></div></div></div><div id="appendixesappgroup1"><h2 id="_appendixesappgroup1_">Appendices</h2><div id="niceng226er12.appa"><h3>Appendix A. Review protocols</h3><p id="niceng226er12.appa.et1"><a href="/books/NBK589218/bin/niceng226er12-appa-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (238K)</span></p></div><div id="niceng226er12.appb"><h3>Appendix B. Literature search strategies</h3><ul><li class="half_rhythm"><div>Is regular follow-up and review needed for people with osteoarthritis?</div></li></ul><p>The literature searches for this review are detailed below and complied with the methodology outlined in Developing NICE guidelines: the manual.<a class="bibr" href="#niceng226er12.ref4" rid="niceng226er12.ref4"><sup>4</sup></a></p><p>For more information, please see the Methodology review published as part of the accompanying documents for this guideline.</p><div id="niceng226er12.appb.s1"><h4>B.1. Clinical search literature search strategy</h4><p id="niceng226er12.appb.et1"><a href="/books/NBK589218/bin/niceng226er12-appb-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (263K)</span></p></div><div id="niceng226er12.appb.s2"><h4>B.2. Health Economics literature search strategy</h4><p id="niceng226er12.appb.et2"><a href="/books/NBK589218/bin/niceng226er12-appb-et2.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (211K)</span></p></div></div><div id="niceng226er12.appc"><h3>Appendix C. Effectiveness evidence study selection</h3><p id="niceng226er12.appc.et1"><a href="/books/NBK589218/bin/niceng226er12-appc-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (118K)</span></p></div><div id="niceng226er12.appd"><h3>Appendix D. Effectiveness evidence</h3><p>No studies were included.</p></div><div id="niceng226er12.appe"><h3>Appendix E. Forest plots</h3><p>No studies were included.</p></div><div id="niceng226er12.appf"><h3>Appendix F. GRADE tables</h3><p>No studies were included.</p></div><div id="niceng226er12.appg"><h3>Appendix G. Economic evidence study selection</h3><p id="niceng226er12.appg.et1"><a href="/books/NBK589218/bin/niceng226er12-appg-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (203K)</span></p></div><div id="niceng226er12.apph"><h3>Appendix H. Economic evidence tables</h3><p>There were no health economic studies found in the review.</p></div><div id="niceng226er12.appi"><h3>Appendix I. Health economic model</h3><p>No original economic modelling was undertaken.</p></div><div id="niceng226er12.appj"><h3>Appendix J. Excluded studies</h3><div id="niceng226er12.appj.s1"><h4>Clinical studies</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng226er12tab3"><a href="/books/NBK589218/table/niceng226er12.tab3/?report=objectonly" target="object" title="Table 5" class="img_link icnblk_img figpopup" rid-figpopup="figniceng226er12tab3" rid-ob="figobniceng226er12tab3"><img class="small-thumb" src="/books/NBK589218/table/niceng226er12.tab3/?report=thumb" src-large="/books/NBK589218/table/niceng226er12.tab3/?report=previmg" alt="Table 5. Studies excluded from the clinical review." /></a><div class="icnblk_cntnt"><h4 id="niceng226er12.tab3"><a href="/books/NBK589218/table/niceng226er12.tab3/?report=objectonly" target="object" rid-ob="figobniceng226er12tab3">Table 5</a></h4><p class="float-caption no_bottom_margin">Studies excluded from the clinical review. </p></div></div></div><div id="niceng226er12.appj.s2"><h4>Health Economic studies</h4><p>Published health economic studies that met the inclusion criteria (relevant population, comparators, economic study design, published 2005 or later and not from non-OECD country or USA) but that were excluded following appraisal of applicability and methodological quality are listed below. See the health economic protocol for more details.</p><p>None.</p></div></div><div id="niceng226er12.appk"><h3>Appendix K. Research recommendations – full details</h3><div id="niceng226er12.appk.s1"><h4>K.1. Research recommendation</h4><p>What is the clinical and cost effectiveness of patient-initiated follow-up compared with routine follow-up for people with osteoarthritis?</p><div id="niceng226er12.appk.s1.1"><h5>K.1.1. Why this is important</h5><p>Evidence in lacking as to the optimal follow up strategy for people with osteoarthritis. In most cases patient initiated follow up is likely to be sufficient however there may be instances where this is not appropriate. The committee considered this might apply to those who have communication difficulties or learning disability; in people with multi-morbidities where osteoarthritis is not seen as a priority and for people where clinicians are uncertain the patient will access care when it is needed. In this review the committee investigated the effect of symptom led follow up and routine follow up and identified no evidence. The committee recommended that patient led follow up was likely to be appropriate for most people. However, the committee agreed that further research was required to ensure that the most optimal follow up was provided for people with osteoarthritis.</p></div><div id="niceng226er12.appk.s1.2"><h5>K.1.2. Rationale for research recommendation</h5><p id="niceng226er12.appk.et1"><a href="/books/NBK589218/bin/niceng226er12-appk-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (187K)</span></p></div><div id="niceng226er12.appk.s1.3"><h5>K.1.3. Modified PICO table</h5><p id="niceng226er12.appk.et2"><a href="/books/NBK589218/bin/niceng226er12-appk-et2.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (177K)</span></p></div></div></div></div></div><div class="fm-sec"><div><p>Final version</p></div><div><p>Evidence reviews underpinning recommendations 1.5.1 to 1.5.3 and research recommendations in the NICE guideline</p></div><div><p><b>Disclaimer</b>: The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.</p><p>Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.</p><p>NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the <a href="http://wales.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Welsh Government</a>, <a href="http://www.scotland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Scottish Government</a>, and <a href="http://www.northernireland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Northern Ireland Executive</a>. All NICE guidance is subject to regular review and may be updated or withdrawn.</p></div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © NICE 2022.</div><div class="small"><span class="label">Bookshelf ID: NBK589218</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/36791243" title="PubMed record of this title" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">36791243</a></span></div></div><div class="small-screen-prev"></div><div class="small-screen-next"></div></article><article data-type="table-wrap" id="figobniceng226er12tab1"><div id="niceng226er12.tab1" class="table"><h3><span class="label">Table 1</span><span class="title">PICO characteristics of review question</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK589218/table/niceng226er12.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng226er12.tab1_lrgtbl__"><table><tbody><tr><th id="hd_b_niceng226er12.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Population</th><td headers="hd_b_niceng226er12.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Inclusion:<ul><li class="half_rhythm"><div>Adults (age ≥16 years) with osteoarthritis affecting any joint</div></li></ul></p>
|
|
<p>Stratification of the population:<dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd><p class="no_top_margin">– People starting a new pharmacological intervention</p></dd></dl><dl class="bkr_refwrap"><dt>2.</dt><dd><p class="no_top_margin">– People starting a new non-pharmacological intervention</p></dd></dl><dl class="bkr_refwrap"><dt>3.</dt><dd><p class="no_top_margin">– Long-term condition management (defined as: people requiring additional management who are not necessarily starting a new pharmacological or non-pharmacological intervention, including people who may be eligible for joint replacement surgery and people who do not want joint replacement surgery but have symptoms that require management).</p></dd></dl></dl></p>
|
|
<p>Exclusion:<ul><li class="half_rhythm"><div>Children (age <16 years)</div></li><li class="half_rhythm"><div>People with conditions that may make them susceptible to osteoarthritis or often occur alongside osteoarthritis (including: crystal arthritis, inflammatory arthritis, septic arthritis, diseases of childhood that may predispose to osteoarthritis, medical conditions presenting with joint inflammation and malignancy).</div></li><li class="half_rhythm"><div>Spinal osteoarthritis</div></li></ul></p>
|
|
</td></tr><tr><th id="hd_b_niceng226er12.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Interventions</th><td headers="hd_b_niceng226er12.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>A) Is regular or symptom-led follow-up most beneficial?<ul><li class="half_rhythm"><div>Structured, regular follow up appointments dedicated to the topic of osteoarthritis (in a United Kingdom primary care setting or relevant equivalent setting in other countries) at a specified frequency.</div></li><li class="half_rhythm"><div>Symptom led follow-up<ul class="circle"><li class="half_rhythm"><div>Pain led follow-up</div></li><li class="half_rhythm"><div>Function led follow-up</div></li></ul></div></li></ul></p>
|
|
<p>B) If regular follow-up is beneficial what is the frequency of follow-up required?</p>
|
|
<p>Frequency will be categorised into the following groups:<ul><li class="half_rhythm"><div>More than once a year</div></li><li class="half_rhythm"><div>Once a year</div></li><li class="half_rhythm"><div>Between six months and once a year</div></li><li class="half_rhythm"><div>Less than six months</div></li></ul></p>
|
|
</td></tr><tr><th id="hd_b_niceng226er12.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparisons</th><td headers="hd_b_niceng226er12.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Compared to each other (including regular follow up compared to symptom led follow up [split by two categories] and different frequencies of follow up)</p>
|
|
<p>Confounding factors (if including non-randomised evidence):<ul><li class="half_rhythm"><div>Age</div></li><li class="half_rhythm"><div>Baseline symptoms such as pain and/or function</div></li><li class="half_rhythm"><div>Baseline BMI (or weight in the absence of BMI)</div></li></ul></p>
|
|
</td></tr><tr><th id="hd_b_niceng226er12.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcomes</th><td headers="hd_b_niceng226er12.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Stratify by ≤/>3 months (longest time-point in each):</p>
|
|
<p>Critical outcomes:<ul><li class="half_rhythm"><div>Health-related quality of life [validated patient-reported outcomes, continuous data prioritised]</div></li><li class="half_rhythm"><div>Pain [validated patient-reported outcomes, continuous data prioritised]</div></li><li class="half_rhythm"><div>Physical function [validated patient-reported outcomes, continuous data prioritised]</div></li></ul></p>
|
|
<p>Important outcomes:<ul><li class="half_rhythm"><div>Psychological distress [validated patient-reported outcomes, continuous data prioritised]</div></li><li class="half_rhythm"><div>Osteoarthritis flares [validated patient-reported outcomes, continuous data prioritised]</div></li><li class="half_rhythm"><div>Falls [dichotomous]</div></li><li class="half_rhythm"><div>Residential service or hospital admission (including disability allowance) [dichotomous]</div></li><li class="half_rhythm"><div>Progression to joint replacement [dichotomous]</div></li></ul></p>
|
|
</td></tr><tr><th id="hd_b_niceng226er12.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study design</th><td headers="hd_b_niceng226er12.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
|
|
<ul><li class="half_rhythm"><div>Systematic reviews of randomised controlled trials (RCTs)</div></li><li class="half_rhythm"><div>RCTs</div></li></ul>
|
|
|
|
<p>If insufficient RCT evidence is available, non-randomised studies will be considered, including:<ol><li class="half_rhythm"><div>Prospective and retrospective cohort studies</div></li></ol></p>
|
|
<p>Studies will only be included if all of the key confounders have been accounted for in a multivariate analysis. In the absence of multivariate analysis, studies that account for key confounders with univariate analysis or matched groups will be considered.</p>
|
|
</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng226er12tab2"><div id="niceng226er12.tab2" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK589218/table/niceng226er12.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng226er12.tab2_lrgtbl__"><table><thead><tr><th id="hd_h_niceng226er12.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Resource</th><th id="hd_h_niceng226er12.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Unit costs</th><th id="hd_h_niceng226er12.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Source</th></tr></thead><tbody><tr><td headers="hd_h_niceng226er12.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">GP cost per consultation lasting 9.22 minutes (including direct care staff costs and qualification costs)</td><td headers="hd_h_niceng226er12.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£39</td><td headers="hd_h_niceng226er12.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PSSRU 2020<a class="bibr" href="#niceng226er12.ref2" rid="niceng226er12.ref2"><sup>2</sup></a></td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng226er12tab3"><div id="niceng226er12.tab3" class="table"><h3><span class="label">Table 5</span><span class="title">Studies excluded from the clinical review</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK589218/table/niceng226er12.tab3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng226er12.tab3_lrgtbl__"><table><thead><tr><th id="hd_h_niceng226er12.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study</th><th id="hd_h_niceng226er12.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Exclusion reason</th></tr></thead><tbody><tr><td headers="hd_h_niceng226er12.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ahn 2016<a class="bibr" href="#niceng226er12.ref1" rid="niceng226er12.ref1"><sup>1</sup></a></td><td headers="hd_h_niceng226er12.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Conference abstract only</td></tr><tr><td headers="hd_h_niceng226er12.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hinman 2020<a class="bibr" href="#niceng226er12.ref3" rid="niceng226er12.ref3"><sup>3</sup></a></td><td headers="hd_h_niceng226er12.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect interventions (follow up for an intervention)</td></tr><tr><td headers="hd_h_niceng226er12.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ravaud 2009<a class="bibr" href="#niceng226er12.ref5" rid="niceng226er12.ref5"><sup>5</sup></a></td><td headers="hd_h_niceng226er12.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inappropriate comparison (compares regular follow up to as many follow up appointments in a limited time period, rather than symptom-led follow up)</td></tr><tr><td headers="hd_h_niceng226er12.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Smith 2015<a class="bibr" href="#niceng226er12.ref6" rid="niceng226er12.ref6"><sup>6</sup></a></td><td headers="hd_h_niceng226er12.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Conference abstract only</td></tr><tr><td headers="hd_h_niceng226er12.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Wang 2021<a class="bibr" href="#niceng226er12.ref7" rid="niceng226er12.ref7"><sup>7</sup></a></td><td headers="hd_h_niceng226er12.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect intervention (predictors for early stage arthritis- all people had imaging. No relevant information for follow-up review)</td></tr><tr><td headers="hd_h_niceng226er12.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Wetzels 2008<a class="bibr" href="#niceng226er12.ref8" rid="niceng226er12.ref8"><sup>8</sup></a></td><td headers="hd_h_niceng226er12.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Inappropriate comparison (compares regular follow up to no follow up)</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal106 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|